An implantable hemodialyzer for treatment of End-Stage Renal Disease

描述（由申请人提供）：终末期肾病（ESRD）影响美国60多万人，每年花费医疗保险约330亿美元。中心内每周三次血液透析是ESRD最常用的治疗方法，但其5年生存率低，患者生活质量降低，且费用昂贵。相比之下，每日延长血液透析的5年生存率与肾移植相似，并改善了中期结局。尽管每日延长血液透析的结局上级中心每周三次血液透析，但只有不到1%的ESRD人群进行，因为在中心进行成本太高，在家中进行太复杂。目前的家庭血液透析系统需要患者和护理人员执行与危及生命的风险相关的复杂任务，例如自我护理针刺。日常扩展家庭血液透析的上级结局但采用率较低，为简单易用且安全的家庭血液透析系统创造了机会。我们项目的长期目标是创建一种新的家庭血液透析系统（nHHD），以增加每日延长家庭血液透析的实践并改善终末期肾病（ESRD）的结局。该NIH SBIR I期提案旨在证明nHHD的可行性，使ESRD患者能够进行每日延长的家庭血液透析，从而获得相关的健康益处。

DESCRIPTION (provided by applicant): End-Stage Renal Disease (ESRD) affects just over 600,000 people in the United States and costs Medicare ~$33 billion annually. In-center thrice-weekly hemodialysis is the most commonly performed treatment for ESRD, but it suffers from poor 5-year survival rates, reduced patient quality of life, and is costly. In contrast, daily-extended hemodialysis has demonstrated 5-year survival rates similar to kidney transplant and has improved intermediate outcomes. Even though daily-extended hemodialysis yields superior outcomes than in- center thrice-weekly hemodialysis, it is performed by less than 1% of the ESRD population because it is too costly to perform in-center and too complex to perform at home. Current home hemodialysis systems require patients and caregivers to perform complicated tasks associated with life threatening risks, such as self-care needle sticks. The superior outcomes but low adoption rate of daily-extended home hemodialysis creates an opportunity for a simple-to-use and safe home hemodialysis system. The long-term objective of our project is to create a new home hemodialysis system (nHHD) that will increase the practice of daily-extended home hemodialysis and improve End-Stage Renal Disease (ESRD) outcomes. This NIH SBIR Phase I proposal aims to demonstrate the feasibility of the nHHD that will empower ESRD patients to perform daily-extended home hemodialysis and consequently receive the associate health benefits.